Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAW1033B2 in Obstructive Sleep Apnea
NCT03426631Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atomoxetine, fesoterodine in obstructive sleep apnea (OSA), sponsored by Brigham and Women's Hospital. Started Sep 2017; status: completed.
02
Drugs
atomoxetinefesoterodine
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT03426631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03426631.